Kriti Nutrients Q1 FY27: board meet, FY26 numbers, outlook

Why Kriti Nutrients is in focus

Kriti Nutrients Ltd is entering the June 2026 quarter (Q1 FY27) results season after reporting steady top-line growth through FY26, while profitability has moved unevenly across quarters. The company has also initiated insider trading compliance steps, including a trading window closure ahead of the results. Separately, a results preview note in the public domain has laid out an estimated revenue and profit range for Q1 FY27.

The immediate trigger is the company’s board process for considering unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. Investors are tracking the timeline, the limited review by auditors, and whether quarterly margin movement stabilises after a softer EBIT trend in the March 2026 quarter.

Board meeting intimation for June 2026 quarter results

A board meeting intimation titled for meeting “02/2026-27” outlines consideration and approval of the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The agenda also includes taking on record the limited review report by the auditors for the unaudited standalone and consolidated results for the same quarter. Any other matter may be taken up with the permission of the chair.

The timeline information in the provided disclosures is mixed. One line states the Board of Directors meeting “02/2026-27” is scheduled for Tuesday, August 1, 2026. But another note says the board meeting date to approve results for the quarter ended June 30, 2026 will be announced later. What is clear is the company has indicated that Q1 FY27 results are to be taken up at a board meeting, along with the auditor limited review.

Trading window closure and SEBI compliance steps

Kriti Nutrients has closed its trading window from July 1, 2026 until 48 hours after the declaration of the unaudited standalone and consolidated financial results for Q1 FY27. The disclosure says this is in line with SEBI insider trading regulations.

The restriction is stated to apply to promoters, directors, key managerial personnel (KMPs), and designated persons. The note also mentions NSDL freezing PANs for the company’s shares during the restricted period. The window is set to remain shut until 48 hours after the results declaration.

Quarterly revenue trajectory through March 2026

Quarterly revenue numbers shared in the data show a rising trend over the last two fiscal years, with the March 2026 quarter at the highest level shown.

The sequence indicates a step-up beginning March 2025, followed by a strong June 2025 quarter, and then a return to growth by March 2026. The pattern matters because Q1 FY27 expectations in the preview note are built using Q1 FY26 as a base and a “most recent year-on-year growth signal from Q4 FY26.”

Recent operating snapshot: income, expenses, EBIT and PAT

A separate summary table provides a recent snapshot of income, expense and operating profit movement, ending March 2026. While total income grew sequentially into March 2026, expenses also rose, and EBIT and PAT were lower than in December 2025.

This data points to a quarter where revenue rose but operating profit declined, suggesting margin pressure in the March 2026 period relative to the immediately preceding quarters.

Consolidated March 2026: sales up, profit higher year-on-year

For the March 2026 quarter on a consolidated basis, the data states net sales at Rs 255.23 crore, up 27.58% year-on-year from Rs 200.05 crore in March 2025. Quarterly net profit is reported at Rs 6.36 crore, up 29.31% from Rs 4.92 crore. EBITDA is stated at Rs 10.92 crore in March 2026, up 36.16% from Rs 8.02 crore. EPS is reported at Rs 1.27 in March 2026 compared with Rs 0.98 in March 2025.

The same set of numbers also lists expenditure line items such as consumption of raw materials, purchase of traded goods, employees cost, and depreciation for Mar 2026 and Dec 2025, reflecting the cost base behind the top-line growth. While the company’s revenue growth is clear in the reported comparison, the quarter-to-quarter EBIT and PAT movement shown earlier indicates investors are likely to focus on cost control and margin stability in Q1 FY27.

FY26 audited results: board approval and audit status

Kriti Nutrients has submitted standalone and consolidated audited financial results for the year ended March 31, 2026 under Regulation 33 of SEBI (LODR), 2015. The disclosure says the results, along with the auditor’s report, statement of assets and liabilities, and cash flow statement, were approved by the Audit Committee and Board of Directors on May 5, 2026.

It also states that the auditor’s report has no modifications or qualifications. The company indicated it is in the process of filing results in XBRL format and will publish them in English and Hindi newspapers.

Full-year performance numbers cited in the data

For the full year ended March 2026, the data states net profit declined 8.35% to Rs 33.90 crore versus Rs 36.99 crore in the year ended March 2025. Over the same period, sales rose 25.49% to Rs 921.51 crore from Rs 734.34 crore.

The combination of higher sales and lower full-year net profit suggests that cost and margin variables remained significant through FY26, even as quarterly sales momentum improved. That context frames the market’s sensitivity to Q1 FY27 margin and profit direction.

Share price references and what they indicate

The data includes multiple price references. One line states Kriti Nutrients share price is Rs 90.01 as on 07 Aug, 2026 (11:48 AM IST) and also says the share price is down by 4.34% based on a previous share price of Rs 89.15. Another section cites “Kriti Nutrients CMP Rs.77” in the results preview note.

Because these numbers appear in different parts of the provided material, they should be treated as separate reference points rather than a single continuous price series. Still, they show that the stock is being actively tracked into the results window, alongside a stated 12-month target range in the preview note.

Q1 FY27 estimates cited in the preview note

A results preview note provides an estimated range for Q1 FY27. It cites Q1 FY27E revenue of Rs 273-314 crore and PAT estimate of Rs 10-13 crore, and mentions a 12-month target of Rs 92-102. The same note says the framework uses the company’s Q1 FY26 base of Rs 231 crore revenue and Rs 9 crore net profit, applying the most recent year-on-year growth signal from Q4 FY26.

The note also says Q1 FY27 results are expected in a July-August 2026 window, aligning with the broader results season for the quarter ending June 2026. These are estimates and an “indicative” window as stated in the material, and the official numbers will come only after the company’s board approval and exchange filing.

Key dates, contact details, and what to watch next

The company’s trading window closure from July 1, 2026 until 48 hours after results sets the compliance frame for the period. Investors will watch for the formal board meeting announcement for the June 2026 quarter results, alongside the limited review report referenced in the agenda.

The material also lists the registered address as Mehta Chambers, 34, Siyaganj, Indore, Madhya Pradesh, 452007, and an email contact of cs@kritiindia.com. From a numbers standpoint, the key watch-items are whether the strong year-on-year sales growth seen in March 2026 carries into June 2026, and whether expenses rise at a slower pace than income, improving EBIT and PAT.

Conclusion

Kriti Nutrients is approaching its Q1 FY27 results with a disclosed process for approving unaudited standalone and consolidated numbers and recording the auditor limited review report. Recent data shows rising quarterly revenue through March 2026, while quarterly profit and EBIT softened sequentially despite higher income. The next confirmed step is the board-led approval and disclosure of the June 2026 quarter results, after which the trading window will reopen 48 hours later as stated in the compliance note.